FindMyKOL
Clinical trialNCT01687218CompletedPhase 2Interventional

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

SponsorCONRADEnrollment195HIV
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

MTN-017 is a Phase 2, multi-site, randomized, six-sequence, two three-period, open label crossover study, examining the effects of oral Truvada and reduced glycerin 1% tenofovir gel. The study population will be sexually active, HIV-uninfected males who are 18 years of age or older, who report a history of receptive anal intercourse in the past 3 months. Each of the study product regimens offers different advantages to participants seeking an effective HIV prevention agent. How these relative advantages will compare in terms of safety, acceptability, systemic and local absorption, and adherence will be examined within this study.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Peru
  • Asociacion Civil Impacta Salud Y Educacion (impacta)

    Lima, Peru

Puerto Rico
  • University of Puerto Rico Medical Sciences Campus - Maternal Infant Studies Center (cemi)

    San Juan, Puerto Rico

South Africa
  • Desmond Tutu Hiv Foundation

    Cape Town, South Africa

Thailand
  • Research Institute for Health Sciences - Chiang Mai University

    Chiang Mai, Thailand

  • Thailand Moph - Us Cdc Collaboration (tuc)

    Nonthaburi, Thailand

United States
  • Hiv Research Section, San Francisco - Department of Public Health

    San Francisco, California, United States

  • the Fenway Institute/fenway Community Health

    Boston, Massachusetts, United States

  • University of Pittsburgh Medical Center (upmc)

    Pittsburgh, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Emtricitabine →Rectal Daily TFV RG 1% gelRectal RAI-associated TFV RG 1% gel
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
25 Sept 2013
Primary completion
26 May 2015
Completion
26 May 2015
Last update posted
24 Jun 2021
Registered enrollment
195
Registry id
NCT01687218
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.